Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHe HuangLZLulu Zhang

Discussion

Loading...

Member takes

Overview

Prospective trial shows 100% objective response rate in treatment-naïve follicular lymphoma, suggesting novel BTK inhibitor therapy is promising.

Key Points

  • This clinical study aims to evaluate safety and efficacy of zanubrutinib with chemoimmunotherapy in advanced follicular lymphoma.
  • Single-arm phase II clinical study enrolling 34 treatment-naïve patients aged 18-75 years
  • Patients received induction therapy with bendamustine, rituximab, and zanubrutinib for six cycles
  • Maintenance therapy included rituximab every 3 months for up to 2 years or until disease progression
  • 80.6% of patients achieved complete response, and 100% objective response rate
  • Median follow-up of 6.6 months with 12-month progression-free survival rate at 83%
  • Most common adverse events included leukopenia and neutropenia, with no treatment-related deaths

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db31https://doi.org/10.1182/blood-2025-5363
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  2. 2Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025
  3. 3Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma2025 · 1 citations
  4. 4Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025
  5. 5ZAP trial: MRD-guided chemotherapy and maintenance de-escalation with zanubrutinib-g-CHOP in high-risk FL (Phase II)2025